Medical/Pharmaceuticals
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality
SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions now affect more than 40% of the population—over 3 billion people, according to WHO's Global Status Report on Neurology, released at the World Congress of Neurology (WCN) inSeoul. The report reveals that neurolog...
2025-10-15 13:32
1097
Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based inShangh...
2025-10-15 08:00
1467
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the E...
2025-10-15 00:00
3194
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
2025-10-14 21:03
3482
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnos...
2025-10-14 21:00
1335
Pictor's Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle
New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management. CARLSBAD, Calif., Oct. 14, 2025 /PRNewswire/ -- Mycoplasma bovis is a devastating pathogen that threate...
2025-10-14 21:00
1097
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...
2025-10-14 20:30
1477
Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing,Zhejiang, bringing together a prestigious gathering of leading minds in ...
2025-10-14 20:30
1646
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...
2025-10-14 20:30
1287
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...
2025-10-14 20:00
2306
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...
2025-10-14 18:18
1726
Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales
Next-Generation solution supports the NHS 10-year Health Plan and the mission
to create a workforce that is fit for the future
LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys
2025-10-14 18:02
1234
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...
2025-10-14 18:00
1674
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...
2025-10-14 14:59
1724
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...
2025-10-14 14:26
1143
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
* In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. * Teli...
2025-10-14 13:44
614
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enro...
2025-10-14 12:13
1559
Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health
XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This ...
2025-10-13 23:00
1433
Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market
TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary,Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology ...
2025-10-13 21:40
1836
iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both t...
2025-10-13 21:00
1266
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 316 media titles]
2026-03-27 11:15
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 310 media titles]
2026-03-24 14:00Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 279 media titles]
2026-03-25 16:51
Noah Reports Q4 and Full Year 2025 Earnings: Structural Transformation Driving Significant Improvement in Profitability as AI Integration Drives Operational Efficiency
[Picked up by 274 media titles]
2026-03-25 21:58